Earnings History Data for Braveheart Bio, Inc. (BRVE) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Braveheart Bio, Inc.
Braveheart Bio Inc. is a clinical-stage biopharmaceutical company. It focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor for the treatment of obstructive HCM and non-obstructive HCM. Braveheart Bio Inc. is headquartered in San Francisco, California.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 08-09-2026 | AH | BRVE | Braveheart Bio, Inc. | 1,956 | -2.51 | -0.25 | 0.00 | Braveheart Bio, Inc. reports Q2 results [9/8/2026 4:04 PM] |
28.94 | -0.47 (-1.60%) |
29.42 | 0.01 (0.04%) |
24.31 - 32.00 | 283,423 | 340,000 | 972 | ||